 |
Clinical Trials |
 |
|
Introduction When you or a loved one is diagnosed with cancer, it is important to know every treatment option available for the most complete care. This may include clinical trials, which are research studies designed to evaluate new cancer prevention and treatment options. These studies are the result of a long and deliberate cancer research process that often takes years. Clinical trials test the safety and effectiveness of new or modified treatments in cancer patients using new drugs, unique approaches to surgery and radiation therapy, or various combinations of treatments. Each clinical trial is designed to find new or better ways to treat cancer patients. It is the opinion of many medical professionals that if you have cancer you should at least consider the available clinical trials along with all your other treatment options. Treatment options provided through clinical trials may not be available any other way. Therefore, if you are not evaluating potential treatments accessible through the clinical trials process alongside current standard therapies, you're simply making a decision without weighing all of your available options. The West Clinic currently has Clinical Trial opportunities in the areas of:
Please click on the area of interest to view the associated trials - A Multicenter, Open-label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatydylserine Monoclonal Antibody in Patients with Refractory Advanced Solid Tumor Malignancies
- Neo-Adjuvant
- Neoadjuvant Weekly nab-paclitaxel (Abraxane) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added Concurrently To Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer
- Adjuvant
- A Randomized, Multi-Center, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
- A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
- Metastatic
- 1st Line
- Phase II Trial of Capecitabine in Combination with Fulvestrant for Postmenopausal Women with Hormone Receptor Positive Metastatic Breast Cancer
- A Randomized, Open-label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer
- 1st or 2nd Line
- A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer
- 1st, 2nd or 3rd Line
- A Phase 3, Multi-Center, Open-label, Randomized Study of Gemcitabine/Carboplatin, with or without BSI-201, in Patients with ER-, PR- and HER2-Negative Metastatic Breast Cancer
- 2nd Line
- A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared when Administered in Combination with Chemotherapy for Patients with Locally advanced or Metastatic Breast Cancer that has Progressed During or After Bevacizumab Therapy
- 2nd or 3rd Line
- Phase I/II Trial of Dasatinib plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
- Phase I/II Trial of Dasatinib plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer (opening soon)
- 1st Line
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5-FU/LV plus Bevacizumab as Maintenance Regimen Following First-Line Therapy for Metastatic Colorectal Cancer
- A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination with mFOLFOX6 to the Efficacy of Bevacizumab in Combination with mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
- A Phase I Trial Evaluating mFOLFOX6 and Avastin with Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
- 1st or 2nd Line
- An Open-Label, Dose-Finding Study to evaluate the Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects with Metastatic Colo rectal Cancer
- 2nd or 3rd Line
- A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC)
- 2nd Line or >
- A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic
- Gastric
- 1st Line
- A Phase 2, Open-label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-Line in Subjects with Advanced Gastric Cancer
- 1st or 2nd Line
- Chemoresponse Assay Validation Trial
- 2nd or 3rd Line
- A Phase I Trial of Oral Metronomic Topotecan in Combination with Oral Pazopanib Utilizing a Daily Dosing Schedule to Treat Recurrent or Persistent Gynecologic Tumors
- CLL
- A Phase III, Open-Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia
- CML
- A Multi-Center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic phase (CML-CP) and a Suboptimal Molecular Response to Imatinib
- Adjuvant
- A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Single-Agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR-Positive Tumors
- Locally Advanced
- Phase 1/2 Study of Pemetrexed (Alimta) plus Carboplatin, or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC)
- Metastatic
- 1st Line
- A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination with Platinum-Based Chemotherapy as First line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
- Randomized, Open-label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
- A Phase 1b/2 Study of AMG 479 in Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
- 1st or 2nd Line
- A Randomized Phase II, Multi-Center, Open-label Trial of PR104 and Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer
- 2nd Line
- Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy
- 1st Line
- A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer
- A Phase 3 Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
- 2nd Line
- A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle as Second-Line Treatment in Patients with Unresectable or Metastatic Melanoma
- 1st Line
- A Randomized Dose Escalation, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine Versus Gemcitabine in Patients with Advanced Pancreatic Cancer
- 1st Line
- A Randomized Phase 2 Study of LY2181308 Sodium in Combination with Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer
- 2nd Line
- A Multicenter, Randomized, Double-blind, Phase 3 Study of Sunitinib Plus Prednisone Versus Prednisone in Patients with Progressive Metastatic Hormone-Refractory Prostate Cancer After Failure or a Docetaxel-Based Chemotherapy Regimen
- A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide plus Doxorubicin Versus Doxorubicin in Subjects with Unresectable or Metastatic Soft-Tissue Sarcoma
Next Section: What are Clinical Trials? » |
|
|
|